OS Therapies (OSTX) Competitors $1.62 0.00 (0.00%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.59 -0.03 (-1.60%) As of 03/28/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX vs. LRMR, CGEN, ZNTL, ACTU, OGI, DERM, ALEC, SAVA, LXEO, and TELOShould you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Larimar Therapeutics (LRMR), Compugen (CGEN), Zentalis Pharmaceuticals (ZNTL), Actuate Therapeutics (ACTU), Organigram (OGI), Journey Medical (DERM), Alector (ALEC), Cassava Sciences (SAVA), Lexeo Therapeutics (LXEO), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. OS Therapies vs. Larimar Therapeutics Compugen Zentalis Pharmaceuticals Actuate Therapeutics Organigram Journey Medical Alector Cassava Sciences Lexeo Therapeutics Telomir Pharmaceuticals OS Therapies (NYSE:OSTX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Does the media refer more to OSTX or LRMR? In the previous week, Larimar Therapeutics had 42 more articles in the media than OS Therapies. MarketBeat recorded 44 mentions for Larimar Therapeutics and 2 mentions for OS Therapies. Larimar Therapeutics' average media sentiment score of 0.07 beat OS Therapies' score of 0.04 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OS Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Larimar Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders believe in OSTX or LRMR? 91.9% of Larimar Therapeutics shares are held by institutional investors. 13.8% of OS Therapies shares are held by company insiders. Comparatively, 3.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate OSTX or LRMR? OS Therapies currently has a consensus price target of $17.50, suggesting a potential upside of 980.25%. Larimar Therapeutics has a consensus price target of $20.22, suggesting a potential upside of 760.52%. Given OS Therapies' stronger consensus rating and higher possible upside, equities analysts plainly believe OS Therapies is more favorable than Larimar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Does the MarketBeat Community favor OSTX or LRMR? Larimar Therapeutics received 38 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 71.43% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformOS TherapiesOutperform Votes7100.00% Underperform VotesNo VotesLarimar TherapeuticsOutperform Votes4571.43% Underperform Votes1828.57% Which has preferable earnings & valuation, OSTX or LRMR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79MN/AN/ALarimar TherapeuticsN/AN/A-$36.95M-$1.30-1.81 Is OSTX or LRMR more profitable? OS Therapies' return on equity of 0.00% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% Larimar Therapeutics N/A -35.87%-32.37% SummaryOS Therapies beats Larimar Therapeutics on 7 of the 13 factors compared between the two stocks. Remove Ads Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OSTX vs. The Competition Export to ExcelMetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$35.26M$6.91B$5.63B$19.37BDividend YieldN/A2.79%5.33%3.76%P/E RatioN/A7.2623.6433.06Price / SalesN/A218.91385.1826.59Price / CashN/A65.6738.1717.55Price / BookN/A6.386.894.53Net Income-$7.79M$142.34M$3.20B$1.02B7 Day Performance-3.57%-5.83%-3.56%-2.58%1 Month Performance-1.82%-7.55%1.51%-4.04%1 Year PerformanceN/A-11.06%9.33%2.55% OS Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OSTXOS Therapies2.1899 of 5 stars$1.62flat$17.50+980.2%N/A$35.26MN/A0.00N/ALRMRLarimar Therapeutics1.9201 of 5 stars$2.28-10.2%$20.13+782.7%-69.0%$145.48MN/A-1.9830Earnings ReportHigh Trading VolumeCGENCompugen1.998 of 5 stars$1.62+3.2%$4.00+146.9%-40.7%$144.56M$27.86M81.0070Positive NewsZNTLZentalis Pharmaceuticals1.9173 of 5 stars$1.98+3.7%$8.24+316.4%-88.5%$141.11M$40.56M-0.80160Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionGap DownACTUActuate TherapeuticsN/A$7.20+6.7%$20.00+177.8%N/A$140.63MN/A0.0010Gap DownOGIOrganigram0.6895 of 5 stars$1.11flatN/A-52.1%$140.10M$166.12M-2.92860DERMJourney Medical2.5269 of 5 stars$6.54+13.9%$9.67+47.8%+66.0%$136.62M$57.77M-6.9690Earnings ReportAnalyst RevisionHigh Trading VolumeALECAlector3.8036 of 5 stars$1.37+1.5%$3.50+155.5%-78.6%$135.75M$100.56M-0.81270Gap UpSAVACassava Sciences3.8707 of 5 stars$2.80-1.4%$111.50+3,882.1%-91.9%$135.26MN/A-2.0330Short Interest ↓LXEOLexeo Therapeutics3.1712 of 5 stars$4.09+50.9%$23.60+477.0%-73.9%$135.24M$650,000.00-1.2958Earnings ReportAnalyst RevisionHigh Trading VolumeTELOTelomir Pharmaceuticals2.3566 of 5 stars$4.53-0.7%$15.00+231.1%-23.3%$134.83MN/A-7.811Gap Down Remove Ads Related Companies and Tools Related Companies Larimar Therapeutics Competitors Compugen Competitors Zentalis Pharmaceuticals Competitors Actuate Therapeutics Competitors Organigram Competitors Journey Medical Competitors Alector Competitors Cassava Sciences Competitors Lexeo Therapeutics Competitors Telomir Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OSTX) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
